Last reviewed · How we verify
Iberogast® and Iberogast® N
Iberogast is a herbal combination product that promotes gastric motility and reduces visceral pain through multiple plant-derived active compounds.
Iberogast is a herbal combination product that promotes gastric motility and reduces visceral pain through multiple plant-derived active compounds. Used for Functional dyspepsia, Irritable bowel syndrome, Gastric motility disorders.
At a glance
| Generic name | Iberogast® and Iberogast® N |
|---|---|
| Also known as | active |
| Sponsor | Hospital Vall d'Hebron |
| Drug class | Herbal combination / Phytopharmaceutical |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Iberogast contains extracts from nine medicinal plants (including Iberis amara, Angelica archangelica, Milk thistle, Chelidonium majus, Caraway, Licorice, Melissa officinalis, Celandine, and Peppermint) that work synergistically to enhance gastric muscle contractions, improve gastric emptying, and modulate visceral pain perception. The formulation acts on multiple targets including smooth muscle function and local inflammatory pathways in the gastrointestinal tract.
Approved indications
- Functional dyspepsia
- Irritable bowel syndrome
- Gastric motility disorders
Common side effects
- Gastrointestinal upset
- Allergic reactions (rare)
- Headache
Key clinical trials
- Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iberogast® and Iberogast® N CI brief — competitive landscape report
- Iberogast® and Iberogast® N updates RSS · CI watch RSS
- Hospital Vall d'Hebron portfolio CI